Drug intelligence / Profile preview

LMP03

Development stage: Preclinical
Lead developer: Curatio
Modality: Small Molecules
Administration: Parenteral

Overview

LMP03 is a preclinical-stage small molecule being developed by Curatio Therapeutics as a disease-modifying osteoarthritis drug (DMOAD). It is designed to target key molecular pathways involved in the progression of osteoarthritis, with the aim of suppressing joint inflammation, promoting cartilage regeneration, and alleviating pain. Preclinical studies in animal models have demonstrated the drug's potential efficacy in modifying the course of the disease rather than just managing symptoms.

Beyond the preview

Go deeper on LMP03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LMP03.

Explore the full profile